Gleave ME - Search Results

1

Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.

Li H, Xie N, Gleave ME, Dong X. Li H, et al. Among authors: gleave me. Oncotarget. 2015 Aug 21;6(24):20474-84. doi: 10.18632/oncotarget.4105. Oncotarget. 2015. PMID: 26009876 Free PMC article.

2

Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP.

Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Sato N, et al. Among authors: gleave me. J Biol Chem. 1997 Jul 11;272(28):17485-94. doi: 10.1074/jbc.272.28.17485. J Biol Chem. 1997. PMID: 9211894 Free article.

3

Differential transactivation by the androgen receptor in prostate cancer cells.

Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Snoek R, et al. Prostate. 1998 Sep 1;36(4):256-63. doi: 10.1002/(sici)1097-0045(19980901)36:4<256::aid-pros7>3.0.co;2-d. Prostate. 1998. PMID: 9719026

4

Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.

Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Gleave ME, et al. Urology. 1999 Dec;54(6A Suppl):36-46. doi: 10.1016/s0090-4295(99)00453-7. Urology. 1999. PMID: 10606283

5

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

Miyake H, Nelson C, Rennie PS, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 Jan 1;60(1):170-6. Cancer Res. 2000. PMID: 10646870

6

Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.

Miyake H, Pollak M, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 Jun 1;60(11):3058-64. Cancer Res. 2000. PMID: 10850457

7

Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.

Sadar MD, Gleave ME. Sadar MD, et al. Among authors: gleave me. Cancer Res. 2000 Oct 15;60(20):5825-31. Cancer Res. 2000. PMID: 11059779

8

Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.

Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL. Bruchovsky N, et al. Among authors: gleave me. Mol Urol. 2000 Fall;4(3):191-9;discussion 201. Mol Urol. 2000. PMID: 11062374 Clinical Trial.

9

Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.

Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Gleave ME, et al. Urology. 2001 Aug;58(2 Suppl 1):39-49. doi: 10.1016/s0090-4295(01)01241-9. Urology. 2001. PMID: 11502446

10

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.

July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. July LV, et al. Among authors: gleave me. Prostate. 2002 Feb 15;50(3):179-88. doi: 10.1002/pros.10047. Prostate. 2002. PMID: 11813210

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

669 results

Search Page

Filters